LONDON, March 5, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge.com has issued free earnings notes on GlaxoSmithKline PLC (NYSE: GSK). On February 04, 2015, the company reported its preliminary financial results for Q4 FY14 and full year FY14 (period ended December 31, 2014). Click on http://get.Investor-Edge.com/pdf/?c=GlaxoSmithKline&d=05-Mar-2015&s=GSK to read our free earnings review on GlaxoSmithKline PLC (GlaxoSmithKline). During Q4 FY14 and full year FY14, the company recorded turnover of £6.19 billion and £23.01 billion, respectively. Our free coverage report can be accessed at:
http://get.Investor-Edge.com/pdf/?c=GlaxoSmithKline&d=05-Mar-2015&s=GSK
Earnings Overview
During Q4 FY14, GlaxoSmithKline's turnover fell by £720 million Y-o-Y from £6.91 billion in Q4 FY13. The company's Q4 FY14 turnover came in slightly above Bloomberg analysts' forecast of £6.16 billion. GlaxoSmithKline's Pharmaceuticals and Vaccines segment turnover fell by £503 million Y-o-Y to £5.07 billion in Q4 FY14. Further, the company's Consumer Healthcare fell by £11 million Y-o-Y to £1.12 billion in Q4 FY14. Free research on GSK can be downloaded in PDF format at:
http://get.Investor-Edge.com/pdf/?c=GlaxoSmithKline&d=05-Mar-2015&s=GSK
In Q4 FY14, GlaxoSmithKline's core operating profit stood at £1.77 billion, lower than Q4 FY13 core operating profit of £2.02 billion. The company's total operating profit was £691 million in Q4 FY14 compared with £2.44 billion in Q4 FY13. GlaxoSmithKline's profit attributable to shareholders came in at £1.03 billion, or 21.3p per diluted share, in Q4 FY14, as compared to £2.46 billion, or 50.4p per diluted share, in Q4 FY13.
For FY14, GlaxoSmithKline's turnover fell by £3.50 billion Y-o-Y from £26.51 billion in FY13. The company's FY14 turnover narrowly missed Bloomberg analysts' forecast of £23.05 billion. GlaxoSmithKline's Pharmaceuticals and Vaccines segment turnover decreased £2.18 billion Y-o-Y to £18.67 billion in FY14. Furthermore, the company's Consumer Healthcare turnover fell £420 million Y-o-Y to £4.34 billion in FY14.
The company's core operating profit stood at £6.59 billion in FY14 compared to £7.77 billion in FY13. The company's total operating profit declined to £3.60 billion in FY14 from £7.03 billion in FY13. GlaxoSmithKline's FY14 profit attributable to shareholders was £2.76 billion, or 56.7p per diluted share, as compared to £5.44 billion, or 110.5p per diluted share, in FY13. Moreover, the company's cash generated from operation was £6.28 billion in FY14 compared to £8.50 billion in FY13. Sign up and read the free analyst's notes on GSK at:
http://get.Investor-Edge.com/pdf/?c=GlaxoSmithKline&d=05-Mar-2015&s=GSK
Sir Andrew Witty, CEO of GlaxoSmithKline, stated that the company started 2015 focused on priorities critical to its performance this year. These include completion of the proposed major 3-part transaction with Novartis, improved commercialization of new products and progression of mid-stage R&D pipeline, capitalizing on product supply resumption in its Consumer business and execution of the Company's pharmaceutical restructuring program, he added.
Mr. Witty informed that GlaxoSmithKline continued to make good progress towards closure of the Novartis transaction, with approval received from the US FTC on most aspects and European clearance now granted, subject to certain divestments. He asserted that for 2014, the company has declared a dividend of 80p, up 3% Y-o-Y, and for 2015 GlaxoSmithKline expects to maintain dividend per share at the same level. In addition, subject to the approvals and conditions set out in the circular sent to shareholders, the company expects to return £4 billion of the net proceeds receivable from Novartis once the transaction has closed, he informed.
During FY14, the company paid dividends to shareholders of £3.84 billion and spent £238 million on repurchasing shares. Visit Investor-Edge and access the latest research on GSK at:
http://get.Investor-Edge.com/pdf/?c=GlaxoSmithKline&d=05-Mar-2015&s=GSK
Stock Performance
On the day of the earnings release, February 04, 2015, GlaxoSmithKline's stock gained 1.56 % ending the session at $44.95. Since then, the stock has moved both ways with gains outperforming losses. On the last close, Wednesday, March 04, 2015, the company's shares finished 0.23% higher at $47.82, after vacillating between $47.34 and $47.99. A total of 3.12 million shares were traded which was below their three months average volume of 4.19 million shares. Over the previous three trading sessions and last one month, GlaxoSmithKline's shares have advanced 0.84 % and 6.38 %, respectively. Further, the stock has gained 4.21 % over the past three months. Shares in GlaxoSmithKline are trading above their 50-day and 200-day moving averages of $44.82 and $47.68, respectively. Moreover, the stock has a Relative Strength Index (RSI) of 63.61.
Sneak Peek to Corporate Insider Trading
In the last one month, GlaxoSmithKline has not reported any share transactions by insiders to the U.S. Securities and Exchange Commission (SEC). Complimentary in-depth research on GSK is available at:
http://get.Investor-Edge.com/pdf/?c=GlaxoSmithKline&d=05-Mar-2015&s=GSK
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article